U.S. Food and Drug Administration (USFDA) has issued warning letter to Glenmark Pharmaceuticals’ Goa (India) facility. The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility. The Company is committed to work along with the USFDA to implement all the necessary corrective actions required to address the concerns at the earliest.
The Company is committed to maintaining the highest quality and compliant manufacturing standards at all of its facilities across the globe.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
